yf_tkr_ALNY · 2026-08-24
Alnylam Pharmaceuticals announced it will present new clinical and real-world data on AMVUTTRA (vutrisiran) and investigational hypertension drug zilebesiran at the European Society of Cardiology Congress 2026 in Munich, following the release of detailed HELIOS-B and KARDIA-3 study analyses. The breadth of ATTR and hypertension data, spanning late-stage trials and real-world evidence, reinforces Alnylam’s RNAi platform reach across serious cardiovascular conditions. We’ll now examine how...
Read the original at yf_tkr_ALNY ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。